One-fi fth of patients with Crohn's disease (CD) are primary non-responders to anti-tumor necrosis factor (anti-TNF) therapy, and an estimated 10-15% will fail therapy annually. Little is known about the genetics of response to anti-TNF therapy. The aim of our study was to identify genetic factors associated with primary non-response (PNR) and loss of response to anti-TNFs in CD.
INTRODUCTION
Crohn's disease (CD) is a chronic relapsing infl ammatory bowel disease (IBD) resulting in progressive bowel damage and disability ( 1 ) . Monoclonal anti-tumor necrosis factor α (anti-TNF) antibodies have revolutionized the care of these patients, enabling achievement of clinical and endoscopic remission, and preventing surgery ( 2 ) . Infl iximab (IFX), adalimumab (ADA), and certolizumab pegol (CZP) have all demonstrated effi cacy in inducing and maintaining remission in clinical trials and are approved for the treatment of moderate-to-severe CD. However, despite their established effi cacy, one-fi ft h of patients will have no response at all to these agents (primary non-response, PNR) and an additional one-third will eventually fail therapy (secondary loss of response), requiring addition or change to another medication or surgery (3) (4) (5) .
Th e exact mechanisms of PNR and secondary loss of response (LOR) remain inadequately defi ned ( 3, 5 ) . Several studies have attempted to identify patient-related or drug-related factors but have yielded hetero geneous results ( 3, 4 ) . Consequently, there is considerable interest and an unmet need for use of genetic markers Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn's Disease
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to predict response to these therapies. Most prior studies examining this question studied only single or a few candidate genes, had small sample sizes, and did not yield defi nitive results (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . Polymorphisms in TNFα ( ref. 10 ) , IBD5 locus ( 14 ) , Immunoglobulin G (IgG) Fc receptor IIIa ( ref. 9 ) , autophagy (ATG16L1; ( ref. 16 ) and apoptosis-related genes ( 7 ) have also been variably associated with a response to IFX or ADA. A limitation of exclusively studying a few candidate loci or IBD-risk alleles alone is the possibility of missing potentially relevant associations across loci that more broadly infl uence immune function across a spectrum of diseases. Such an analysis may be particularly pertinent given the effi cacy of anti-TNF agents across a range of immune-mediated diseases that only modestly share risk loci and pathogenic pathways.
Th e need for identifi cation of genetic predictors of response to therapy achieves additional urgency with the growing availability of drugs with distinct mechanisms of action. Identifying relevant predictors would allow stratifi cation of patients by likelihood of response to anti-TNF therapy, thereby directing them to other drugs if there is a low pre-test probability of response. Using a large, prospective cohort with detailed genotype information, we performed this study with the following aims: (1) to identify single nucleotide polymorphisms (SNPs) predicting PNR and durable clinical response (DR) in CD patients initiating anti-TNF therapy; and (2) to compare the utility of clinical and genetic factors in predicting PNR and DR.
METHODS
Study population
Th e Prospective Registry in IBD Study at Massachusetts General Hospital (PRISM) is a prospective cohort of patients with IBD receiving care at the MGH Crohn's and Colitis center; details of the cohort have been previously described ( 17 ) . On providing informed consent, information on demographics, disease characteristics including date of diagnosis, IBD type, disease location and phenotype, and treatment characteristics are obtained for each patient. A total of 427 patients identifi ed from this database met our criteria for inclusion in this study: (1) CD diagnosed using standard criteria; (2) received anti-TNF therapy with IFX, ADA, or CZP, and (3) genotyping performed on the Illumina Immunochip. For patients who had received more than one anti-TNF therapy, only data from their fi rst anti-TNF exposure was included.
Outcomes
Using chart review by study investigators (G.E.B., A.N.A.), we characterized the patients' response to their fi rst anti-TNF therapy using clinical, radiological, endoscopical, and laboratory data that were available. PNR was defi ned as non-response by 12 weeks aft er starting therapy accompanied by an alteration of therapeutic approach (addition or escalation of corticosteroids, switch to a diff erent agent, or surgery). All patients received standard induction dosing (infl iximab 5 mg/kg at weeks 0, 2, and 6; ADA 160 mg at week 0, 80 mg at week 2; CZP 400 mg at weeks 0, 2, and 4). DR was defi ned as maintenance of response to anti-TNF therapy for at least 24 months aft er initiation. Only patients who achieved at least partial initial response were included in analysis of DR. Th is was done as the underlying mechanisms for PNR (for example, non-TNF-dependent infl ammatory pathways) may be distinct from that for DR (such as immunogenicity). Th us, separating out the two cohorts minimized the potential for bias owing to mechanisms contributing to PNR. However, in a sensitivity analysis we classifi ed all primary non-responders as not meeting DR. For patients who ceased treatment due to adverse eff ects before the 24-month time point, we classifi ed them as non-responders if the adverse events were related to loss of response (for example, infusion reactions due to immunogenicity) or excluded them from the analyses for those that were unrelated to response (non-CD related infections, insurance reasons). Patients requiring dose escalation who responded could be classifi ed as having DR if they remained on therapy for 24 months. To perform internal validation of our fi ndings, we also calculated time to cessation of therapy irrespective of reason for stopping therapy.
Clinical covariates
Information was extracted on age, gender, smoking status, duration of disease at anti-TNF initiation, location and phenotype of IBD according to the Montreal classifi cation, and presence of perianal involvement. Information was also obtained on prior therapies and whether index anti-TNF agent was used as monotherapy or in conjunction with an immunomodulator (azathioprine, 6-mercaptopurine, methotrexate; combination immunosuppression (IS)).
Genotyping
All patients provided 10 ml of blood for extraction of buff y coat from which genomic DNA was isolated. Genotyping was performed on the Illumina Immunochip at the Broad Institute (Cambridge, MA). Th e Immunochip is a custom-designed platform to perform deep replication of infl ammatory and autoimmune loci covering 196,524 polymorphisms putatively associated with immune function or autoimmune diseases.
Statistical analysis
Th e study was approved by the Institutional Review Board of Partners Healthcare. Clinical covariates were summarized using means and s.d. 's. Categorical variables were summarized using proportions. Comparison between those with PNR or DR to those without was done using the t -test for continuous and the χ 2 test for categorical variables. Univariate logistic regression was performed to identify variables signifi cant at P <0.10 for inclusion in the multivariable model.
Genetic analysis was performed using Plink v1.07 ( ref. 18 ). All SNPs met the Hardy-Weinberg equilibrium threshold of P >0.001, genotyping call rate >99% and genotyping success rate >80%. Genotype-phenotype analysis was performed in two steps. First, candidate polymorphisms associated with PNR or DR among the 163 IBD-risk alleles ( 19 ) were selected as signifi cant at a P value<0.05. A more rigorous threshold of P <1×10 −4 was used for the other immunochip loci. Next, a genetic risk score (GRS) was calculated based on the allele burden (∑risk allele haplotypes) with
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separate scores for PNR and DR. Th en, the GRS was entered into the multivariable model along with relevant clinical covariates. We compared the performance of a combined model including clinical and genetic data to those including clinical variables alone and GRS alone using the area under the receiver operating characteristics curve (AUROC) and the likelihood ratio test. To test the consistency of our fi ndings, we performed internal validation in two steps. First, we included the SNPs identifi ed using logistic regression and genetic association analysis in a Cox proportional hazards models with time to cessation of anti-TNF therapy. Second, we repeated the analysis using bootstrapping with 10,000 replications. All statistical analysis was performed using Stata 13.2 (StataCorp, College Station, TX).
RESULTS
Study population
Among 359 patients with suffi cient data to assess PNR, 36 had PNR (10%). Objective data (laboratory testing, radiological imaging, and endoscopic evaluation) were available for this determination in 186 patients with determination being made based on clinical symptoms in the remaining. Th e mean age was 25.7 years and mean disease duration before fi rst anti-TNF therapy was 10.6 years. Just over half were women (59%). Ileocolonic involvement was the most common site (57%) and an equal proportion had infl ammatory or penetrating disease (38% each). Th e most common fi rst anti-TNF therapy was infl iximab (82%), and about half were on combination IS. Among 274 patients in whom we could defi ne durable response, 73% met this end point; objective data was available for making this determination in 149 patients.
Predictors of primary non-response
Patients with and without PNR were similar in gender, disease behavior, perianal involvement, type of anti-TNF therapy, use of combination IS, or history of prior resection ( Table 1 ) . However, primary non-responders were more likely to have had longer disease duration before initiating anti-TNF therapy (15 vs. 10 years), were older at diagnosis (29 vs. 25 years), and more likely to be smokers (53% vs. 33%). Isolated colonic involvement was also more common among primary non-responders (42%) compared with responders (22%) ( P =0.03).
On genetic association analysis, 11 IBD-risk alleles met a P value threshold<0.05 and four additional SNPs on the immunochip met a threshold of P <1×10 −4 and were incorporated into the GRS ( Supplementary Table 1 online) . Th is yielded a PNR GRS that ranged from 5 to 20 in our cohort. Primary non-responders had a signifi cantly higher GRS than patients without PNR (16.4 vs. 11.2, P =8×10 −12 ; Figure 1 ). On multivariable analysis including relevant clinical covariates, the PNR GRS was the only significant independent predictor of PNR (odds ratio (OR) 2.65, 95% confi dence interval (CI) 1.94-3.61, P =6×10 −10 ). Two clinical variables, disease duration at anti-TNF initiation (OR 1.04, 95% CI 1.00-1.09, P =0.07) and ileocolonic (vs. ileal) location (OR 0.30, 95% CI 0.08-1.18, P =0.09) demonstrated a trend towards statistical signifi cance ( Figure 1 ). Re-defi ning PNR with a more specifi c defi nition of absence of response and therapy cessation within 4 months of induction did not alter any of our fi ndings. Excluding CZP users from our analysis ( n =14) as this medication had not shown statistically signifi cant eff ect in inducing remission in the pivotal RCTs did not modify our association between the GRS AND PNR ( P =1×10 −11 ).
Predictors of durable response
A history of prior resection was more common in patients without DR compared with those with DR (66% vs. 42%, P <0.001) with none of the other clinical covariates meeting statistical signifi cance ( Table 3 ) . On genetic association analysis, 16 SNPs (11 IBD-risk alleles, 5 other loci on the immunochip) predicted DR, Anti-TNF, anti-tumor necrosis factor therapy; CD, Crohn's disease; PNR, primary non-response.
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Genetics of Anti-TNF Response in Crohn's Disease including those at the IL2RA and ATG16L1 loci ( Supplementary  Table 2 ). Th e durable response GRS ranged from 6 to 23 in our cohort. Combining the risk alleles, patients achieving DR had a higher DR GRS than those who did not achieve DR (15.0 vs. 11.2, P =7×10 −13 ). On multivariable analysis, only the GRS and a lack of prior resections were independently predictive of durable response ( Table 4 ) . Each 1 point increase in the GRS was associated with a 60% increase in likelihood of DR (OR 1.60, 95% CI 1.41-1.83, P =2×10 −12 ). Combination IS use demonstrated a trend towards a higher likelihood of DR (OR 1.89, 95% CI 0.94-3.83). A combined clinical-genetic model (AUROC 0.85) was superior to a clinical only (AUROC 0.66, P <0.001) or genetics only model (AUROC 0.83, P <0.001; Supplementary Figure 2 ). Our fi ndings were robust on internal validation on bootstrapping with 10,000 replications. Including primary non-responders as not meeting DR did not alter these associations.
Time to anti-TNF therapy cessation
In a Cox proportional hazards analysis, a lower GRS (fewer alleles predicting DR) predicted earlier cessation of anti-TNF therapy on univariate (hazard ratio 0.90, 95% CI 0.86-0.94, P =2×10 −7 ) and multivariable analysis (hazard ratio 0.89, 95% CI 0.85-0.93, P =4×10 −8 ). A total of 47% of patients in the lowest quartile of the GRS achieved DR compared with 97% of patients in the highest quartile (hazard ratio 0.40, 95% CI 0.27-0.59, P =3×10 −6 ) ( Figure 2 ).
Polymorphisms associated with PNR and DR are exclusive to their respective outcome
Genetic risk scores for PNR could not predict DR ( P =0.71) and vice versa ( P =0.72, ρ =0.02), suggesting that the mechanisms underlying the genetic predisposition to PNR and DR are distinct. Th e overall burden of CD genes as calculated previously ( 17 ) also did not predict either PNR or DR ( P =0.97 and 0.77, respectively). Th e presence of a NOD2 mutation was not associated with PNR (OR 0.32, 95% CI 0.08-1.25) or DR (OR 2.11, 95% CI 0.91-4.90). Anti-TNF, anti-tumor necrosis factor therapy; CD, Crohn's disease; CI, confi dence interval; GRS, genetic risk score; OR, odds ratio; PNR, primary non-response.
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nf-kB-dependent transcript induced by TNFα in regulatory T-cells that down-regulates T-cell mediated suppression of infl ammation ( 24 ) . Th e retinoic-acid related orphan receptor is downregulated on treatment with IFX and plays a role in mucosal healing through down-regulation of Th 1/Th -17 associated infl ammatory cytokine production ( 25 ) . IFX administration also down-regulates IL1R1, IL1R2, and IL18 receptor complex ( 26, 27 ) ; polymorphisms at all these sites were associated with PNR in our study. Th e T-cell activation RhoGTPase activating protein, associated with loss of response in our cohort, was also shown to be diff erentially downregulated on colon biopsies of responders to IFX when compared with non-responders ( 28 ). Similar to previously published studies, we found that patients with long-standing disease before initial TNF therapy and smoking were associated with PNR ( ref. 12 ). Curiously, isolated colonic involvement had previously been associated with better response to anti-TNF (albeit not focusing on PNR), whereas in our cohort colonic disease was more common in PNR ( ref. 29 ) . Combination IS demonstrated a trend towards DR consistent with recent literature demonstrating reduce immunogenicity and higher rates of response with dual immunosuppression ( 2, 30 ) . Results have been variable in prior clinical studies were potentially relevant parameters identifi ed including gender and disease location, smoking, longer disease duration, and stricturing disease ( 12 ) .
Another interesting fi nding from our study is that although genetic factors predicted both PNR and DR, no alleles were common to both analyses. In addition, the PNR GRS was not predictive of DR and vice versa, suggesting that the mechanisms behind PNR and DR are distinct. Mechanistically, a signifi cant proportion of patients with secondary LOR have sub-therapeutic trough levels oft en driven by anti-drug antibodies. Th is is supported by the trend towards an inverse association between combination IS use and DR in our cohort and in prior studies ( 30, 31 ) . In contrast, PNR is oft en seen despite adequate level of drug during induction therapy supporting the hypothesis of a distinct infl ammatory pathway in that subset of patients. Further in evidence of this is that in
DISCUSSION
Given the signifi cant likelihood of primary or secondary nonresponse to anti-TNF agents and with growing availability of therapies targeting CD through diverse pathways, there is an important unmet need to defi ne predictors and mechanisms of response to each therapeutic class. Using a large prospective cohort of CD patients, we demonstrate several SNPs to be associated with PNR and maintenance of DR to anti-TNF therapy. In addition, prediction models incorporating genetics were signifi cantly more accurate in predicting PNR and DR than clinical covariates alone.
Th ere are several novel hypothesis-generating observations from our study. First, we demonstrated that 31 distinct SNPs could be used to predict response to anti-TNF therapy in CD while clinical covariates alone had only modest value. A few prior studies have examined the utility of genetics to predict response to anti-TNF therapy, though they oft en analyzed only a target set of candidate genes (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) 20 ) . Although Niess et al. reported an association between NOD2 mutations and response to IFX ( ref. 21 ) , other studies including ours failed to identify such an association ( 15, 22 ) . Hlavaty et al. identifi ed an association between apoptosisrelated genes including Fas ligand-843, Fas -670, and caspase 9 and response to IFX therapy ( 7 ) . Consistent with this, we found a SNP at the CARD11 locus, a caspase recruitment domain-containing protein to be associated with non-response. Th e CARD11 protein interacts with BCL10 , a signaling protein that regulates apoptosis and nF-kB mediated signaling ( 23 ) . Our study also replicated the previously described association between the ATG16L1 polymorphism and response to anti-TNF therapy ( 16 ) .
Several other loci off er mechanistic plausibility by virtue of their importance in regulating TNFα -mediated infl ammatory responses. Th e TNF receptor super family 9 (TNFRSF 9) is an Anti-TNF, anti-tumor necrosis factor therapy; CD, Crohn's disease; CI, confi dence interval; GRS, genetic risk score; OR, odds ratio. 
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Genetics of Anti-TNF Response in Crohn's Disease patients with prior anti-TNF exposure, those with PNR demonstrate low rates of response to subsequent anti-TNF agents ( 32 ) . Th ere are several implications to our fi ndings. First, the association between genetics and response to anti-TNF therapy off ers the potential to better understand the biological mechanisms for heterogeneity in response. Th is may also help identify novel pathways to serve as target for future therapies. It is possible that genetics may also be useful in diff erentiating slow responders from early complete responders, a question that merits addressing in future prospective studies. Second, it is possible that the genetic polymorphisms infl uence drug response through their eff ect on drug clearance or immunogenicity. We did not have information on drug trough levels and antibody (as many patients were on treatment before this testing became routine). It is important to examine this association in future studies. Th ird, the signifi cant improvement in predictive value with genetics, particularly for PNR, off ers the potential to tailor therapy to individuals based a priori on likelihood of response. Th is allows us to accurately balance risks of therapy with likelihood of benefi t. In addition, with growing availability of therapies with distinct mechanisms of action, this approach allows for potentially matching the patient to the drug.
We readily acknowledge several limitations to this study. First, our defi nitions of PNR and DR were by chart review rather than prospectively collected disease activity indices. However, this is also a strength as we used comprehensive clinical, endoscopic, and radiological evidence to adjudicate response status rather than relying on symptom based activity indices alone that notoriously correlate poorly with objective disease activity. In addition, objective information was available for review in a signifi cant proportion of patients. A misclassifi cation between responders and non-responders would likely bias towards the null, making our estimates conservative. Future studies should prospectively include endoscopic, fecal, and serological evaluations to defi ne response. In addition, our fi ndings were consistent in analyses using time to cessation of therapy as an outcome which is a hard outcome not infl uenced by the retrospective design of our study. Second, we could not assess adherence or episodic use which may aff ect effi cacy. Th ird, in this hypothesis-generating study, we selected a less rigorous P value threshold for genetic association analysis than has been used in genome-wide associated studies. Th us, there is a need for external validation in other cohorts. Fourth, we did not have information on anti-drug antibody in the vast majority of our patients and so could not explore the genetics of this phenomenon. Th e number of patients with PNR was small. However, a post hoc power calculation revealed >99% power in detecting a signifi cant diff erence for both our PNR and DR analyses. Heterogeneity between patient characteristics such as type of anti-TNF agent and disease phenotype may infl uence associations; however our fi ndings were robust on adjustment for these in a multivariable model and statistically signifi cant associations were noted for both IFX and ADA individually on a sensitivity analysis. Similarly, repeating the analysis including only patients with an infl ammatory disease phenotype retained statistical signifi cance of our associations. Physician-level practice variation including selection and optimization of therapy may have additionally infl uenced rates of durable response; we were not able to account for this in our analysis. Other predictors such as C-reactive protein, hemoglobin, or serum albumin were not available at anti-TNF initiation in a signifi cant proportion of patients and thus could not be included as covariates. Finally, our enrollees may have more severe CD than the general population by virtue of seeking care at a referral center.
In conclusion, in a large CD cohort, we identifi ed risk alleles that predicted PNR and durable response to anti-TNF therapies. A composite genetic score of risk alleles was successful in predicting response to therapy and had greater accuracy and performance than clinical covariates. Further work is required to validate our fi ndings in other cohorts, following which such genetic markers may be useful in personalizing therapy in CD to ensure optimal outcomes for our patients.
